The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related semaglutide-based drugs, Ozempic and Wegovy – since 2022 amid unprecedented demand.
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Related Posts
-
Republicans say they will defer to Trump on Iran war despite arrival of 60-day deadline
Under the War Powers Resolution of 1973, Congress must declare war or authorize the use…
-
Samsung Networks has one of its worst quarters since 5G was born
Revenues fall one quarter at Samsung’s networks business, which blames ‘headwinds’ and says ‘cost discipline’…
-
Predictability of telco cloud spend still a ‘touchy subject’
Execs from Vodafone Intelligent Services and Hrvatski Telekom shed light on some of the cloud…
-
Dramatic video shows car upside down in a creek after crash
Video from the scene shows the wrecked vehicle overturned in the water as a witness…
Leave a Reply